These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 38885227)
1. A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation. Simon ST; Lin M; Trinkley KE; Aleong R; Rafaels N; Crooks KR; Reiter MJ; Gignoux CR; Rosenberg MA PLoS One; 2024; 19(6):e0303261. PubMed ID: 38885227 [TBL] [Abstract][Full Text] [Related]
2. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. Weeke P; Mosley JD; Hanna D; Delaney JT; Shaffer C; Wells QS; Van Driest S; Karnes JH; Ingram C; Guo Y; Shyr Y; Norris K; Kannankeril PJ; Ramirez AH; Smith JD; Mardis ER; Nickerson D; George AL; Roden DM J Am Coll Cardiol; 2014 Apr; 63(14):1430-7. PubMed ID: 24561134 [TBL] [Abstract][Full Text] [Related]
3. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. Schwartz PJ; Woosley RL J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690 [TBL] [Abstract][Full Text] [Related]
4. Dofetilide-induced long QT and torsades de pointes. Aktas MK; Shah AH; Akiyama T Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063 [TBL] [Abstract][Full Text] [Related]
6. The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants. Lopez-Medina AI; Chahal CAA; Luzum JA Pharmacogenomics; 2022 Jun; 23(9):543-557. PubMed ID: 35698903 [TBL] [Abstract][Full Text] [Related]
7. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study. Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480 [TBL] [Abstract][Full Text] [Related]
8. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation. Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046 [TBL] [Abstract][Full Text] [Related]
10. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Ramirez AH; Shaffer CM; Delaney JT; Sexton DP; Levy SE; Rieder MJ; Nickerson DA; George AL; Roden DM Pharmacogenomics J; 2013 Aug; 13(4):325-9. PubMed ID: 22584458 [TBL] [Abstract][Full Text] [Related]
11. Drug-induced QT interval prolongation in patients with heart failure with preserved ejection fraction. Huang CY; Overholser BR; Sowinski KM; Jaynes HA; Kovacs RJ; Tisdale JE PLoS One; 2024; 19(8):e0308999. PubMed ID: 39159176 [TBL] [Abstract][Full Text] [Related]
12. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients. Fan W; Liu H; Shen Y; Hong K Cardiovasc Drugs Ther; 2024 Jun; 38(3):517-525. PubMed ID: 36625987 [TBL] [Abstract][Full Text] [Related]
13. Interpretable Machine Learning Prediction of Drug-Induced QT Prolongation: Electronic Health Record Analysis. Simon ST; Trinkley KE; Malone DC; Rosenberg MA J Med Internet Res; 2022 Dec; 24(12):e42163. PubMed ID: 36454608 [TBL] [Abstract][Full Text] [Related]
14. Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case-control study. Lopez-Medina AI; Campos-Staffico AM; A Chahal CA; Volkers I; Jacoby JP; Berenfeld O; Luzum JA Pharmacogenomics; 2024 Feb; 25(3):117-131. PubMed ID: 38506312 [TBL] [Abstract][Full Text] [Related]
16. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. Jacobson I; Carlsson L; Duker G J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointes. Krisai P; Vlachos K; Ramirez FD; Nakatani Y; Nakashima T; Takagi T; Kamakura T; Surget E; André C; Cheniti G; Welte N; Chauvel R; Tixier R; Duchateau J; Pambrun T; Derval N; Hocini M; Jaïs P; Haïssaguerre M; Sacher F J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2696-2701. PubMed ID: 32700358 [TBL] [Abstract][Full Text] [Related]
18. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies. Jaiswal A; Goldbarg S Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399 [TBL] [Abstract][Full Text] [Related]
19. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949 [TBL] [Abstract][Full Text] [Related]
20. Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program. Sugrue A; Kremen V; Qiang B; Sheldon SH; DeSimone CV; Sapir Y; Striemer BL; Brady P; Asirvatham SJ; Ackerman MJ; Friedman P; Noseworthy PA Cardiovasc Drugs Ther; 2015; 29(5):433-41. PubMed ID: 26411977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]